Ayurvedic formulations containing benzoic and ascorbic acids as additives: benzene formation during storage and impact of additives on quality parameters.

OBJECTIVES: Ayurvedic formulations are becoming the prior choice of people as health care supplements. The increasing demand for these formulations has led to extensive development of Ayurvedic pharmaceutical industries worldwide. The reaction between the preservatives (sodium benzoates and ascorbic acid) used in these formulations could generate benzene. Benzene is classified as class-1 human carcinogen and responsible for various short and long term health effects. METHODS: In this study, 25 formulations (containing ascorbic acid and sodium benzoate) of various manufacturers available as over the counter products were obtained and their benzene content were determined using gas chromatograph with flame ionization detector. RESULTS: The result showed that 64% of the formulations were free from benzene contamination whereas 36% of formulations were found to be contaminated with benzene. A simple, less time-consuming, economic, and validated gas chromatographic method for estimation of benzene in Ayurvedic formulations was also developed successfully in present study. CONCLUSIONS: The data revealed that the level of benzene was within permissible limits, yet the presence of a carcinogen in the marketed formulations intended for internal use is an alarming situation.

Bioinformatics-Based Tools and Software in Clinical Research: A New Emerging Area.

Nowadays, drug discovery is a long process which includes target identification, validation, lead optimization, and many other major/minor steps. The huge flow of data has necessitated the need for computational support for collection, storage, retrieval, analysis, and correlation of data sets of complex information. At the beginning of the twentieth century, it was cumbersome to elaborate the experimental findings in the form of clinical outcomes, but current research in the field of bioinformatics clearly shows ongoing unification of experimental findings and clinical outcomes. Bioinformatics has made it easier for researchers to overcome various challenges of time-consuming and expensive procedures of evaluation of safety and efficacy of drugs at a much faster and economic way. In the near future, it may be a major game player and trendsetter for personalized medicine, drug discovery, drug standardization, as well as food products. Due to rapidly increasing commercial interest, currently probiotic-based industries are flooding the market with a range of probiotic products under the banner of dietary supplements, natural health products, food supplements, or functional foods. Most of the consumers are attracted toward probiotic formulations due to the rosy picture provided by the media and advertisements about high beneficial claims. These products are not regulated by pharmaceutical regulatory authorities in different countries of origin and are rather regulated as per their intended use. Lack of stipulated quality standard is a major challenge for probiotic industry; hence there would always be a possibility of marketing of ineffective and unsafe products with false claims. Hence it is very important and pertinent to ensure the safety of probiotic formulations available as over-the-counter (OTC) products for ignorant society. At the same time, probiotic industry, being in its initial stages in developing and underdeveloped countries, requires to ensure safe, swift, and successful usage of probiotics. In the absence of harmonized regulatory guidelines, safety, quality, as well as the efficacy of the probiotic strain does not remain a mandate but becomes a choice for the manufacturer. Hence there is an urgent need to screen already marketed probiotic formulations for their safety with respect to specific strains of probiotic. Various conventional methods used by the manufacturers for the identification of probiotic microbes create a blurred image about their status as probiotics. The present manuscript focuses on a bioinformatics-based technique for validation of marketed probiotic formulation using 16s rRNA sequencing and strain-level identification of bacterial species using Ez Texan and laser gene software. This technique gives a clear picture about the safety of the product for human use.

Ethanol content in traditionally fermented ayurvedic formulations: Compromised Good Manufacturing Practice regulations - compromised health.

BACKGROUND: A large part of the population of India prefers the traditional medicine (ayurvedic formulations) for primary health care. However, the effective quality control of herbal medicine is still a big challenge. Numerous reports indicate noncompliance with Compromised Good Manufacturing Practice (GMP) guidelines by the manufacturers which may lead to adverse drug reactions or toxic effects. Asava and arishta are the classical herbal dosage forms wherein fermentation occurs during production leading to the generation of ethanol. The presence of ethanol in these preparations may lead to their misuse. The self-generated ethanol is responsible for extraction of active constituents and acts as a self-preservative. As the procedure for preparation for asava and arishta is same, the ethanol content is also expected to be the same irrespective of the manufacturer. OBJECTIVE: The objective of the present study was to assess and compare the ethanol content of some traditionally fermented ayurvedic formulations available in the market. METHOD: In this study, 20 formulations from 3 different manufacturers available as over-the-counter products were obtained and their ethanol contents were determined using gas chromatograph with flame ionization detector. RESULTS: Statistically significant differences were noted in the ethanol content of various ayurvedic formulations. A simple, less time-consuming, economic, and validated gas chromatographic method for estimation of ethanol in fermented ayurvedic formulations was also developed successfully in present study. CONCLUSION: The data generated during study reflected poor compliance of GMP guidelines by the manufacturers and hence the quality is being grossly compromised posing a safety hazard.

Antidiabetic activity of Passiflora incarnata Linn. in streptozotocin-induced diabetes in mice.

ETHNOPHARMACOLOGICAL RELEVANCE: The present study was designed to investigate the hypoglycemic and hypolipidemic properties of Passiflora incarnata Linn. leaves which are widely used as traditional treatment for diabetes mellitus. MATERIALS AND METHODS: The methanolic extracts of leaves of Passiflora incarnata were administered orally (100 and 200 mg/kg, for 15 days) to streptozotocin-induced diabetic mice. Hypoglycemic effects, oral glucose tolerance test, change in body weight and lipid profile of diabetic mice treated with methanolic extracts were assessed and compared with normal, diabetic control and standard drug treated mice. Histological examination during 15 days of treatment was also carried out. RESULTS: Methanolic extract (200 mg/kg) produced a significant reduction in fasting blood glucose level in streptozotocin-induced diabetic mice. Significant differences were also observed in urine glucose level, oral glucose tolerance test, serum lipid profile and body weight of methanolic extract treated diabetic mice, when compared with diabetic, normal and standard drug treated mice. Histopathological studies of the pancreas showed comparable regeneration of the cells by extract which were earlier necrosed by streptozotocin. CONCLUSION: Methanolic extract of Passiflora incarnata exhibit significant anti-hyperglycemic and hypolipidemic activities in streptozotocin-induced diabetes in mice.